Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015

Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020

Published:2021-12-16 Issue: Volume: Page:1-11
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Huntington Scott F.¹,Ingham Michael P.²,Okonkwo Linda³,Singh Ajaybir⁴,Wang Ruibin²⁵,Ammann Eric M.³

Affiliation:

1. Yale School of Medicine, New Haven, CT, USA

2. Janssen Scientific Affairs, Titusville, NJ, USA

3. Janssen Research & Development, Raritan, NJ, USA

4. Mu Sigma, Bangalore, India

5. Harvard T.H. Chan School of Public Health, Boston, MA, USA

Funder

Janssen Pharmaceuticals

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.2012666

Reference26 articles.

1. Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness

2. National Cancer Institute. Cancer stat facts: leukemia — acute myeloid leukemia (AML) surveillance, epidemiology, and end results program; 2020. Available from: https://seer.cancer.gov/statfacts/html/amyl.html.

3. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

4. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia;Cancer Chemotherapy and Pharmacology;2024-03-02

2. Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia;Biomedicine & Pharmacotherapy;2022-09